However, some studies have confirmed that compared with clopidogrel, the new P2Y2 inhibitor significantly reduced the incidence of stent thrombosis, all-cause mortality, and myocardial infarction, while the bleeding risk increased.[28] There are some differences in the use of P2Y12 inhibitors in DAPT in the early stage, which could also be an important limitation of this study. Here, P2RY2 is linked to myocardial infarction.